NEW YORK – Healthcare informatics company Massive Bio announced on Thursday that it has received a Small Business Innovation Research contract from the National Cancer Institute to further develop an artificial intelligence-based platform for matching patients to cancer clinical trials.
The firm will use the contract toward improving its Deep Learning Clinical Trial Matching System, including SYNERGY-AI, a registry that leverages AI to identify patients eligible for clinical trials and matches them to studies based on genomic biomarkers, multivariate analyses, and clinical information from medical records. The company envisions that SYNERGY-AI can be used over time in both academic and community oncology settings.
Massive Bio markets its AI-powered clinical trial matching services, including patient recruitment, site selection, real-world data, and AI-based prescreening to pharmaceutical companies, contract research organizations, and providers.
Richard Carvajal, director of experimental therapeutics at Columbia University Irving Medical Center, said in a statement that in using Massive Bio's trial matching services, he believes that the AI-enabled platform can support his center's goal of "enrolling as many patients as possible" in clinical trials.
Massive Bio added in a statement that its services may be particularly valuable during the COVID-19 pandemic, which has slowed clinical trial enrollment.